Therapeutics in Huntington's Disease

被引:12
|
作者
Killoran, Annie [1 ]
Biglan, Kevin M. [1 ]
机构
[1] Univ Rochester, Sch Med & Dent, Movement & Inherited Neurol Disorders Unit, Dept Neurol, Rochester, NY 14620 USA
关键词
Huntington's disease; Huntington disease; Chorea; Treatment; Therapy; Tetrabenazine; Neuroleptics; Haloperidol; Juvenile Huntington's disease; Pharmacologic treatment; Trinucleotide repeat disorder; RANDOMIZED CONTROLLED-TRIAL; MOUSE MODEL; MOTOR; LEVETIRACETAM; RIVASTIGMINE; RISPERIDONE; PROGRESSION; IMPROVEMENT; OLANZAPINE; EFFICACY;
D O I
10.1007/s11940-012-0165-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
There is no specific treatment for Huntington's disease (HD). Its many symptoms of motor, psychiatric, and cognitive deterioration are managed with symptomatic relief, rehabilitation, and support. The only drug approved by the US Food and Drug Administration (FDA) for the treatment of HD is an antichoreic agent, tetrabenazine, but this drug is used sparingly because of uneasiness regarding its propensity to cause depression and suicidality in this population, which is already at risk for these complications. Neuroleptics are still first-line treatments for chorea accompanied by comorbid depression and/or behavioral or psychotic symptoms, as is often the case. Psychiatric features, which have a significant impact on a patient's professional and personal life, often become the major focus of management. In addition to neuroleptics, commonly used medications include antidepressants, mood stabilizers, anxiolytics, and psychostimulants. In contrast, few treatment options are available for cognitive impairment in HD; this remains an important and largely unmet therapeutic need. HD patients typically lack insight into their disease manifestations, failing to recognize their need for treatment, and possibly even arguing against it. Multipurpose medications are employed advantageously to simplify the medication regimen, so as to facilitate compliance and not overwhelm the patient. For example, haloperidol can be prescribed for a patient with chorea, agitation, and anorexia, rather than targeting each symptom with a different drug. This approach also limits the potential for adverse effects, which can be difficult to distinguish from the features of the disease itself. With HD's complexity, it is best managed with a multidisciplinary approach that includes amovement disorders specialist, a genetic counselor, a mental health professional, a physical therapist, and a social worker for support and coordination of services. As the disease progresses, there may be need for other specialists, such as a speech and occupational therapist, a nutritionist for weight loss, and ultimately, a palliative care specialist.
引用
收藏
页码:137 / 149
页数:13
相关论文
共 50 条
  • [1] Therapeutics in Huntington’s Disease
    Annie Killoran
    Kevin M. Biglan
    [J]. Current Treatment Options in Neurology, 2012, 14 : 137 - 149
  • [2] Emerging therapeutics in Huntington's disease
    Wiggins, Robert
    Feigin, Andrew
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2021, 26 (03) : 295 - 302
  • [3] Identifying new therapeutics for Huntington's disease
    Schilling, G
    Borchelt, DR
    [J]. CLINICAL NEUROSCIENCE RESEARCH, 2003, 3 (03) : 179 - 186
  • [4] Therapeutics for huntington's disease: A systematic review
    Mestre, T.
    Ferreira, J.
    Coelho, M.
    Rosa, M. M.
    Sampaio, C.
    [J]. MOVEMENT DISORDERS, 2007, 22 : S30 - S30
  • [5] Huntington's Disease: New Frontiers in Therapeutics
    Pan, Ling
    Feigin, Andrew
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2021, 21 (03)
  • [6] Huntington's Disease: Latest Frontiers in Therapeutics
    Saade, Joseph
    Mestre, Tiago A.
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2024, 24 (08) : 255 - 264
  • [7] Huntington's disease: new hope for therapeutics
    McMurray, CT
    [J]. TRENDS IN NEUROSCIENCES, 2001, 24 (11) : S32 - S38
  • [8] Therapeutics for Huntington's disease: a systematic review
    Mestre, T. A.
    Ferreira, J. J.
    Coelho, M.
    Rosa, M. M.
    Sampaio, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 98 - 98
  • [9] Huntington’s Disease: New Frontiers in Therapeutics
    Ling Pan
    Andrew Feigin
    [J]. Current Neurology and Neuroscience Reports, 2021, 21
  • [10] Huntington's disease: From basic science to therapeutics
    Cepeda, Carlos
    Tong, Xiao-Ping
    [J]. CNS NEUROSCIENCE & THERAPEUTICS, 2018, 24 (04) : 247 - 249